The only 5 things in Cronos Group’s Q3 earnings update that really matter

Hint: Tremendous revenue growth wasn’t one of them.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article was originally published on Fool.com

Even with all of the excitement leading up to the launch of Canada’s recreational marijuana market, Cronos Group (NASDAQ:CRON) still had its day-to-day business to run. The cannabis producer enjoyed a strong second quarter, with revenue skyrocketing and earnings soaring. But when Cronos reported its third-quarter results on Tuesday, there were a few chinks in the armor.

The company continued to experience solid sales momentum in Q3, with revenue jumping 186% year over year and nearly 11% higher than the second quarter. However, Cronos Group posted a net loss of 7.27 million Canadian dollars (about $5.5 million), compared to positive earnings in the prior-year period and in the previous quarter.

These numbers weren’t the important takeaways from Cronos Group’s Q3 earnings report, though. Here are the five things in the company’s quarterly update that really matter. 

Canadian maple leaf shadow on a pile of marijuana leaves

IMAGE SOURCE: GETTY IMAGES.

1. The loss should be temporary

If Cronos Group’s big loss in the third quarter was a sign of things to come, investors would have a good reason to be concerned. But the loss should only be temporary. 

Total operating expenses increased by a whopping 242% year over year. And the spending increases occurred in every area of the business. However, this higher spending was to be expected as Cronos ramped up for the opening of the recreational marijuana market in Canada. You can think of the spending increases — and the associated net loss — as an investment that should generate a solid return in the not-too-distant future.

2. Higher capacity is coming

One major reason for the increased spending was Cronos Group’s production capacity expansion. Perhaps the best news for the company in the third quarter was the completion of Building 4 at its Peace Naturals facility in Stayner, Ontario. This building adds another 286,000 square feet of indoor growing space. The first harvest is expected by the end of 2018. 

Once Building 4 is operating at its peak, Cronos Group should be able to produce around 40,000 kilograms (just over 88,000 pounds) of cannabis per year. The company’s other expansion initiatives are projected to boost annual production capacity to over 117,000 kilograms within the next couple of years. 

3. Cronos should be able to sell all it produces

Here’s the really important thing to know about Cronos Group’s added capacity: The company should be able to sell its entire production for a while. Cronos secured supply agreements for the recreational marijuana market with Ontario, British Columbia, Nova Scotia, and Prince Edward Island. These provinces have over half of Canada’s total population.

Cronos Group also entered into a supply agreement earlier this year with Cura Cannabis Solutions. This deal requires Cura to purchase a minimum of 20,000 kilograms of cannabis each year over a five-year period.

4. Partnerships could pay off in a big way

It’s quite possible that the partnerships Cronos Group formed during the third quarter will mean a lot more to the company over the long run than its Q3 financial results. One of those partnerships focused on adding production capacity — a joint venture with a group of investors led by greenhouse operator Bert Mucci. However, the other two deals could also be key for Cronos Group’s future success.

In September, Cronos announced a partnership with Ginkgo Bioworks to produce cultured high-purity cannabinoids from engineered strains of yeast. If successful, this effort would enable Cronos to produce cannabinoids at a dramatically lower price than current methods allow. In August, Cronos teamed up with Colombian agricultural company Agroidea SAS in a deal that opens more doors in the Latin American cannabis market. 

5. More dilution is likely on the way

So far, everything that really matters with Cronos Group’s Q3 update has been positive. There is one glaring potential negative development that could be on the way, though. Cronos Group reported cash of CA$43.8 million. This total, combined with the company’s CA$28.7 million construction loan, should fund operations at least through the next 12 months. But it seems likely that Cronos will need to raise more cash at least by sometime in 2020.

Based on the company’s history, this additional capital will probably come from issuing new shares. Although Cronos Group shouldn’t have a problem generating all the money it needs, doing so comes at a price for shareholders: The value of all existing shares will be diluted.

The big picture

The common thread throughout all five of these key items from Cronos Group’s Q3 update is that there’s a bigger picture for the company than just one quarter. What really matters for Cronos — and investors — is how the company grows over the long term.

Cronos Group’s long-term prospects hinge on its capacity, its distribution channels (both in Canada and in international markets), and its innovation. The company’s advances on these fronts during the third quarter will matter a lot more a few years from now than its Q3 revenue increase and net loss.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

 

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »